Blar i Bergen Open Research Archive på forfatter "Vujkovac, Bojan"
-
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: Findings from the opinion-based PREDICT-FD modified Delphi consensus initiative
Hughes, Derralynn A.; Aguiar, Patricio; Deegan, Patrick B; Ezgu, Fatih; Frustaci, Andrea; Lidove, Olivier; Linhart, Aleš; Lubanda, Jean-Claude; Moon, James C; Nicholls, Kathleen; Niu, Dau-Ming; Nowak, Albina; Ramaswami, Uma; Reisin, Ricardo; Rozenfeld, Paula; Schiffmann, Raphael; Svarstad, Einar; Thomas, Mark; Torra, Roser; Vujkovac, Bojan; Warnock, David G.; West, Michael L; Johnson, Jack; Rolfe, Mark J; Feriozzi, Sandro (Journal article; Peer reviewed, 2020)Objectives The PRoposing Early Disease Indicators for Clinical Tracking in Fabry Disease (PREDICT-FD) initiative aimed to reach consensus among a panel of global experts on early indicators of disease progression that may ... -
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
Linhart, Aleš; Dostalova, Gabriela; Nicholls, Kathy; West, Michael; Tøndel, Camilla; Jovanovic, Ana; Giraldo, Pilar; Vujkovac, Bojan; Geberhiwot, T; Brill-Almon, Einat; Alon, Sari; Chertkoff, Raul; Rocco, Rossana; Hughes, Derralynn A. (Journal article; Peer reviewed, 2023)Background Pegunigalsidase alfa is a novel, PEGylated α-galactosidase-A enzyme-replacement therapy approved in the EU and US to treat patients with Fabry disease (FD). Objective/methods BRIDGE is a phase 3 open-label, ...